ATE536406T1 - Neuartiger zytokin-zcytor17-ligand - Google Patents

Neuartiger zytokin-zcytor17-ligand

Info

Publication number
ATE536406T1
ATE536406T1 AT10168189T AT10168189T ATE536406T1 AT E536406 T1 ATE536406 T1 AT E536406T1 AT 10168189 T AT10168189 T AT 10168189T AT 10168189 T AT10168189 T AT 10168189T AT E536406 T1 ATE536406 T1 AT E536406T1
Authority
AT
Austria
Prior art keywords
seq
amino acid
acid residues
novel cytokine
zcytor17 ligand
Prior art date
Application number
AT10168189T
Other languages
English (en)
Inventor
Cindy A Sprecher
Joseph L Kuijper
Maria M Dasovich
Francis J Grant
Angela K Hammond
Jane A Gross
Stacey R Dillon
Rolf Kuestner
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE536406T1 publication Critical patent/ATE536406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
AT10168189T 2002-01-18 2003-01-21 Neuartiger zytokin-zcytor17-ligand ATE536406T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35032502P 2002-01-18 2002-01-18
US37532302P 2002-04-25 2002-04-25
US43531502P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
ATE536406T1 true ATE536406T1 (de) 2011-12-15

Family

ID=27407940

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08102636T ATE478944T1 (de) 2002-01-18 2003-01-21 Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
AT10168189T ATE536406T1 (de) 2002-01-18 2003-01-21 Neuartiger zytokin-zcytor17-ligand
AT03729693T ATE401390T1 (de) 2002-01-18 2003-01-21 Zytokin (zcytor17-ligand)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08102636T ATE478944T1 (de) 2002-01-18 2003-01-21 Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03729693T ATE401390T1 (de) 2002-01-18 2003-01-21 Zytokin (zcytor17-ligand)

Country Status (21)

Country Link
US (12) US7064186B2 (de)
EP (3) EP1476541B1 (de)
JP (1) JP4795641B2 (de)
KR (1) KR101013401B1 (de)
CN (2) CN101843895A (de)
AT (3) ATE478944T1 (de)
AU (2) AU2003225525B2 (de)
BR (1) BR0306979A (de)
CA (1) CA2473686C (de)
CY (1) CY1112833T1 (de)
DE (2) DE60333963D1 (de)
DK (3) DK1961811T3 (de)
ES (3) ES2310660T3 (de)
IL (3) IL163066A (de)
NO (1) NO332266B1 (de)
PL (1) PL211833B1 (de)
PT (1) PT2230299E (de)
RU (2) RU2360923C2 (de)
SI (1) SI2230299T1 (de)
WO (1) WO2003060090A2 (de)
ZA (1) ZA200405695B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (de) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Neues Hämopoietin Receptorprotein, NR10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
DK1961811T3 (da) 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
EP2840089A1 (de) * 2002-01-18 2015-02-25 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
WO2005040380A1 (ja) * 2003-10-29 2005-05-06 Bml, Inc. げっ歯類動物の免疫応答調節蛋白質
JP2007068402A (ja) * 2003-12-26 2007-03-22 Bml Inc 免疫応答調節蛋白質
CA2580084A1 (en) * 2004-11-03 2006-05-18 Boehringer Ingelheim Pharmaceuticals, Inc. T cell proteins and nucleotides encoding the same
JP2008528039A (ja) * 2005-01-28 2008-07-31 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１の均質調製物
EP1858924A1 (de) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Verfahren zur behandlung von hauterkrankungen mit einem il-31ra-antagonisten
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
WO2006088955A2 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
CA2604852A1 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
KR101443050B1 (ko) * 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2749571A3 (de) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Verfahren zur Behandlung von Schmerzen und Entzündungen in Nervengewebe mithilfe von IL-31RA- und OSMRb-Antagonisten
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2548714T3 (es) * 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
US8278056B2 (en) 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
JP2010515755A (ja) 2007-01-10 2010-05-13 ザイモジェネティクス， インコーポレイテッド 気道過敏および喘息を処置するためのｉｌ−３１の使用法
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
WO2009052487A2 (en) * 2007-10-18 2009-04-23 University Of South Florida Method of detecting oncogenesis of hematopoietic cells
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ME03057B (de) 2007-12-07 2019-01-20 Zymogenetics Inc Für IL-31 spezifische humanisierte Antikörpermoleküle
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー／エス ハイブリダイゼーション組成物及び方法
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2826789A1 (de) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten Region eines Antikörpers
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2742127B1 (de) * 2011-08-12 2019-10-09 Mello Biotechnology, Inc. Induzierbare expression in prokaryonten von dem eukaryotischen promotor pol-2
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
EP3142692B1 (de) * 2014-05-12 2019-05-01 Technion Research & Development Foundation Limited Zusammensetzungen mit il-31 und verwendungen davon
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
CN104826100A (zh) * 2015-04-16 2015-08-12 浙江海隆生物科技有限公司 一种猪瘟病毒重组亚单位疫苗的制备方法与应用
DE102015215840B4 (de) * 2015-08-19 2017-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multiaperturabbildungsvorrichtung, Abbildungssystem und Verfahren zum Bereitstellen einer Multiaperturabbildungsvorrichtung
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
TWI765431B (zh) * 2020-11-25 2022-05-21 長庚大學 核酸放大系統及其方法
EP4367226B1 (de) * 2021-07-07 2026-02-11 Vib Vzw Kristallstrukturen von alk- und ltk-rezeptortyrosinkinasen und deren liganden
US12509510B2 (en) 2024-04-23 2025-12-30 Attovia Therapeutics, Inc. IL31-binding polypeptides and uses thereof
WO2026055142A1 (en) 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13 and il31 bispecific polypeptides and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054646A (en) * 1973-07-30 1977-10-18 General Electric Method and apparatus for detection of antibodies and antigens
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE3578435D1 (de) 1984-12-06 1990-08-02 Labofina Sa Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6217857B1 (en) * 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
RU2102988C1 (ru) * 1995-02-10 1998-01-27 Зинченко Елена Вениаминовна Препарат с иммуномодулирующими свойствами
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US5965389A (en) 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast
US6265184B1 (en) * 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
JP2002515746A (ja) 1996-07-17 2002-05-28 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの形質転換
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
EP1185641A1 (de) * 1999-05-11 2002-03-13 ZymoGenetics, Inc. Zytokinrezeptor zcytor10 der maus
EP2325316B8 (de) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Neues Hämopoietin Receptorprotein, NR10
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412239C (en) 2000-06-26 2013-05-28 Zymogenetics, Inc. Cytokine receptor zcytor17
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002223182B2 (en) 2000-10-06 2007-08-30 Immunex Corporation Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
EP2840089A1 (de) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Zytokinrezeptor Zyctor17-Multimere
DK1961811T3 (da) 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
WO2006078714A2 (en) * 2005-01-19 2006-07-27 Irm Llc Multi-well container positioning devices, systems, computer program products, and methods
JP2008528039A (ja) 2005-01-28 2008-07-31 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１の均質調製物
EP1858924A1 (de) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Verfahren zur behandlung von hauterkrankungen mit einem il-31ra-antagonisten
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2749571A3 (de) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Verfahren zur Behandlung von Schmerzen und Entzündungen in Nervengewebe mithilfe von IL-31RA- und OSMRb-Antagonisten
ES2548714T3 (es) 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
JP2010515755A (ja) 2007-01-10 2010-05-13 ザイモジェネティクス， インコーポレイテッド 気道過敏および喘息を処置するためのｉｌ−３１の使用法
ME03057B (de) * 2007-12-07 2019-01-20 Zymogenetics Inc Für IL-31 spezifische humanisierte Antikörpermoleküle

Also Published As

Publication number Publication date
BR0306979A (pt) 2004-11-23
DE60322188D1 (de) 2008-08-28
EP1476541B1 (de) 2008-07-16
CA2473686A1 (en) 2003-07-24
US20030224487A1 (en) 2003-12-04
SI2230299T1 (sl) 2012-07-31
US20190338020A1 (en) 2019-11-07
US20060141579A1 (en) 2006-06-29
AU2003225525A1 (en) 2003-07-30
EP2230299A1 (de) 2010-09-22
WO2003060090A3 (en) 2004-04-01
DK1476541T3 (da) 2008-11-03
EP1961811A1 (de) 2008-08-27
US20090149635A1 (en) 2009-06-11
NO20043419L (no) 2004-10-18
ZA200405695B (en) 2005-03-30
CY1112833T1 (el) 2016-02-10
US20130156695A1 (en) 2013-06-20
PL371586A1 (en) 2005-06-27
IL163066A (en) 2011-08-31
US7531636B2 (en) 2009-05-12
WO2003060090A2 (en) 2003-07-24
IL210454A (en) 2014-02-27
IL210455A (en) 2014-02-27
KR20040082394A (ko) 2004-09-24
RU2360923C2 (ru) 2009-07-10
CN101843895A (zh) 2010-09-29
US7064186B2 (en) 2006-06-20
PL211833B1 (pl) 2012-06-29
JP4795641B2 (ja) 2011-10-19
JP2005526494A (ja) 2005-09-08
US7507795B2 (en) 2009-03-24
DE60333963D1 (de) 2010-10-07
CN100575482C (zh) 2009-12-30
US20110196128A1 (en) 2011-08-11
RU2008118227A (ru) 2009-11-20
US9605062B2 (en) 2017-03-28
DK2230299T3 (da) 2012-03-26
AU2003225525B2 (en) 2008-07-24
CN1643138A (zh) 2005-07-20
US8778344B2 (en) 2014-07-15
US7740834B2 (en) 2010-06-22
US20070249020A1 (en) 2007-10-25
US20180155418A1 (en) 2018-06-07
ATE401390T1 (de) 2008-08-15
US20150010946A1 (en) 2015-01-08
RU2490276C2 (ru) 2013-08-20
PT2230299E (pt) 2012-03-02
IL210455A0 (en) 2011-03-31
IL210454A0 (en) 2011-03-31
ES2377188T3 (es) 2012-03-23
NO332266B1 (no) 2012-08-13
US8013124B2 (en) 2011-09-06
EP1961811B1 (de) 2010-08-25
US20070077627A1 (en) 2007-04-05
CA2473686C (en) 2011-09-20
ATE478944T1 (de) 2010-09-15
US7425325B2 (en) 2008-09-16
EP1476541A2 (de) 2004-11-17
ES2351678T3 (es) 2011-02-09
EP1476541A4 (de) 2006-01-11
AU2008230054A1 (en) 2008-11-13
US8124378B2 (en) 2012-02-28
US20090192292A1 (en) 2009-07-30
KR101013401B1 (ko) 2011-02-14
ES2310660T3 (es) 2009-01-16
DK1961811T3 (da) 2010-11-08
EP2230299B1 (de) 2011-12-07
AU2008230054B2 (en) 2012-01-19
RU2004125165A (ru) 2005-04-20
US7459293B2 (en) 2008-12-02
US20070111266A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
ATE536406T1 (de) Neuartiger zytokin-zcytor17-ligand
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
ATE263778T1 (de) Niedrigallergene proteinvarianten
HUP0100094A1 (hu) Új felületi antigén
ATE441666T1 (de) Antikírper gegen den fibroblastenwachstumsfaktor 23
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
ATE403726T1 (de) Cytokin-proteinfamilie
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
WO2002102847A1 (fr) Nouveau ligand et son adn
AU2003202489A1 (en) Screening method
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant